Podcast

Diabetes Dialogue: April 2022 Edition

Author(s):

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of the FDA's approval of semaglutide 2.0 mg, the use of novel glycemic control metrics, and a preview of ATTD 2022.

Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on Spotify and Apple Podcasts.

Related Videos
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Related Content
Hiddo Heerspink, PharmD, PhD | Credit: George Institute for Global Health
October 25th 2024

Semaglutide Shows Promise, Reduces UACR in Nondiabetic Kidney Disease

Patrick Campbell
Square thumbnail for Kidney Compass podcast featuring headshots of hosts and HCPLive logos
October 21st 2024

Kidney Compass: Navigating Clinical Trials

Brendon Neuen, MBBS, PhD Shikha Wadhwani, MD, MS
Will Herrington, MA, MBBS, MD, FRCP, FERA, Professor of Trials and Epidemiology of Kidney Disease, Renal Studies Group, Nuffield Department of Population Health, and practicing Honorary Consultant Nephrologist, Oxford Kidney Unit, Oxford University
October 25th 2024

Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation

Victoria Johnson
Default thumbnail for The Medical Sisterhood with Mona Shahriari, MD
October 18th 2024

The Medical Sisterhood: Motherhood in Medicine, with Alexandra Golant, MD

Mona Shahriari, MD, FAAD
AND017 Receives FDA Orphan Drug Designation for Sickle Cell Disease | Image Credit: US Food and Drug Administration
October 25th 2024

AND017 Receives FDA Orphan Drug Designation for Sickle Cell Disease

Connor Iapoce
Long-Term Tralokinumab Safe, Effective After 6 Years for Atopic Dermatitis
October 25th 2024

Long-Term Tralokinumab Safe, Effective After 6 Years for Atopic Dermatitis

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.